Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 8/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | CTSL | P07711 | 1/20 | 0.61 |
| ▸ | CTSB | P07858 | 1/20 | 0.61 |
| ▸ | CTSS | P25774 | 1/20 | 0.61 |
| ▸ | CTSK | P43235 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.59 |
| ▸ | ATM | Q13315 | 2/20 | 0.57 |
| ▸ | PPID | Q08752 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4770866 | 0.88 | ANPEP (0.79) | ANPEPALDH1A1LMNACTSLCTSB | |
| SCHEMBL4770883 | 0.88 | ANPEP (0.79) | ANPEPALDH1A1LMNACTSLCTSB | |
| SCHEMBL5869443 | 0.84 | ATM (0.75) | ANPEPALDH1A1LMNACTSLCTSB | |
| SCHEMBL8248836 | 0.84 | ATM (0.75) | ANPEPALDH1A1LMNACTSLCTSB | |
| SCHEMBL1792750 | 0.82 | PSMB5 (0.54) | ANPEPALDH1A1CTSKMAPTPSMB5 | |
| SCHEMBL1792753 | 0.82 | PSMB5 (0.54) | ANPEPALDH1A1CTSKMAPTPSMB5 | |
| SCHEMBL23775651 | 0.82 | ANPEP (0.73) | ANPEPALDH1A1LMNACTSLCTSB | |
| SCHEMBL24446776 | 0.80 | ANPEP (0.67) | ANPEPALDH1A1LMNACTSLCTSB | |
| SCHEMBL6941568 | 0.79 | PSMB8 (0.61) | ALDH1A1CTSLCTSBCTSSMAPT | |
| SCHEMBL23754991 | 0.79 | ANPEP (0.68) | ANPEPALDH1A1LMNACTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | TRPV4, TRPC4, TRPV1 | ANPEP 1609/4885ALDH1A1 1565/4885LMNA 3671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.